The Russian pharmaceutical market is developing rapidly. Annually its volume increases by about 14-15%. At the same time, there are many problems in this industry that should be dealt with, including by the government of the Russian Federation.
Structure of the pharmaceutical market
The Russian pharmaceutical market consists of commercial and government segments. The second, in comparison with the first, includes sales not only through pharmacies, but also through medical institutions and within the framework of the supplementary drug provision program. The commercial segment is characterized by annual positive dynamics and is considered one of the most intensively developing sectors of the country's economy. For example, the growth for the first five months of 2015 compared to the same period in 2014 was 22.6%.
The pharmaceutical market of the Russian Federation has a complex structure. It interacts with:
- consumers (patients and medical workers);
- intermediaries (wholesale and retail distributors of medicines);
- health authorities different countries;
- drug manufacturers.
Features of the pharmaceutical market
- A high share of traditional generic drugs (with the composition and form of original drugs, but without patent protection) and the prevalence of over-the-counter drugs.
- The transition of most enterprises to the manufacture of finished medicines. But due to insufficient experience in the development of their own drugs, a narrow range and low quality of products, they cannot press foreign players on the market.
- In developed Western countries, the main expenses for the purchase of medicines are covered by medical insurance; in Russia, they are borne by end users.
- The tendency of the population to herbal medicine, self-treatment, buying cheap medicines.
Problems of the Russian pharmaceutical market
- Insufficient solvency of the population due to instability in the country's economy.
- Imperfect regulation of the industry at the legislative level.
- A large number of counterfeit drugs.
- Lack of state funding for drug supply programs, as well as support for Russian manufacturers.
- Increased level of competition in the market.
The current state of the pharmaceutical market of the Russian Federation
The volume of imported products is 43 times higher than the volume of goods exported. The main countries-suppliers of medicines to Russia are Germany, Poland, Austria.
The share of over-the-counter drugs in total sales is 47% in monetary terms and 71% in physical terms (packages).
Shares of consumed medicines depending on the cost:
- up to 50 rubles / pack - 10%;
- 50-150 rub./pack. -24%;
- 150-500 rubles/pack — 44%;
- from 500 rub./pack. - 22%.
The volume of the pharmaceutical market in Russia by segments for 1-3 quarter. 2015
TOP-10 Anatomical-Therapeutic-Chemical (ATC)-groups of the 1st level in terms of the share of sales in the retail commercial sector, based on the results of 1-2 quarters. 2015
TOP-10 trade names by share of sales in the retail commercial sector, based on the results of 1-2 quarters 2015
Portrait of a consumer of pharmaceutical products
44% of Russians prefer domestically produced pharmaceutical products, for 42% the country of manufacture does not matter. A large share of medicines from Russian companies falls on consumers from villages and small towns. This is due to their lower cost compared to imported drugs.
Approximately half of the population of the Russian Federation purchases pills and other medicines in pharmacies, and on a weekly basis. Most of the customers are older women. Difficulties in purchasing medicines are experienced by 25% of the inhabitants of the Russian Federation.
When choosing a drug, about 60% of consumers are guided by the recommendations of doctors, but at the same time they rely on their own experience (41%), heed the advice of pharmacists (18%) and relatives (17%). Only 34% of the population believe that doctors prescribe drugs based solely on the health of their patients.
The group of medicines that Russians most often buy on their own, without consulting a doctor, includes vitamins, medicines for headaches and coughs, and nasal drops. On the recommendation of a specialist, antibiotics, antifungal drugs, anti-allergens, and oral contraceptives are most often purchased.
The main players in the pharmaceutical market
There are three groups of participants in the Russian drug market:
- manufacturers (domestic and foreign);
- distributors (wholesale suppliers);
- retail pharmacies (individual outlets and pharmacy chains).
About 75% of the pharmaceutical market is occupied by medicines from foreign manufacturers. The largest share of products from Russian manufacturers falls on the Vital and Essential Drugs group (essential and essential drugs).
In 2015, the Novartis International AG corporation became the leader among manufacturers, producing Sandimmun (to improve the quality of organ transplant operations), Sandostatin (used for stomach bleeding), as well as Voltaren Emulgel, known to most Russians, Teraflu", "Lamisil", "Dlyanos", "Fenistil".
The second position was taken by the Sanofi company, which manufactures the medicines Essentiale, Festal, No-shpa, Amaril, and others.
TOP-10 manufacturers by the share of sales in the retail commercial sector, based on the results of 1-2 quarters. 2015
Distributors play an important role in the development of the pharmaceutical market. Thanks to a wide network of branches, they can provide medicines to residents of many regions of the Russian Federation. The leaders among distributors are Katren and Protek, whose total market share in 2015 exceeded 31%.
TOP-10 distributors by market share of shipments to final recipients (including preferential deliveries), based on the results of 1-2 quarters 2015
In the retail segment of the pharmaceutical market, about 40% are municipal and state pharmacies. But in the near future, this figure will decrease, as the share of private pharmacy chains is growing (for example, Miracle Doctor, Apteki 36.6, etc.)
Pharmaceutical holdings are being formed on the market, for example, Otechestvennye lekarstva OJSC (has a controlling stake in four manufacturing enterprises), Profit House (owns manufacturing enterprises and a retail sales network).
Russian pharmaceutical market development forecast for 2016
Increasing market share of products Russian production
Thanks to the expansion of the production of low-cost domestic drugs and generics, the share of imported products on the market in physical terms will decrease and will be approximately 41%.
Localization of foreign enterprises on the territory of the Russian Federation
The appearance of foreign investors is predicted, who will be able not only to organize their production in Russia, but also to transfer their own technologies to domestic companies. However, localization will have slow pace and carried out only subject to the observance of warranty obligations on the part of Russian enterprises.
Changes in legislation
It is expected that the state will take legislative measures aimed at tightening the access of foreign medicines to the Russian market, as well as supporting domestic manufacturers.
Raising the price of medicines
According to the amendments to the Law “On the Circulation of Medicines” adopted in 2015, indexation of producer prices will be carried out depending on the inflation rate. The average price of medicines may increase by about 16%, and the increase in cost may affect about 90% of medicines from the list of Vital and Essential Drugs.
Get a free consultation or order a branding agencyKOLORO right now!
Medicines will always be on sale. Financial and economic crises can correct the volume or range of sales, however, their impact on the pharmacy market is not as great as in other types of trade.
The volume and share of the Moscow pharmacy market in the all-Russian
In order to get an idea of the Moscow pharmacy market, it is advisable to consider three aspects: the number of outlets, the volume of sales, and the best-selling drugs.
Number of pharmacies
The latest 2GIS statistics confirm the leadership of the Moscow pharmacy market in Russia in terms of the number of outlets. Their number in the capital at the beginning of 2017 is 7268. St. Petersburg is expected to take the second place, in which 1705 pharmacies operate. It is easy to calculate that in terms of the number of retail outlets, Moscow is more than 4 times greater than the northern capital, the difference with other Russian cities is even greater.
However, in relative terms, when calculating the number of pharmacies per 100 thousand inhabitants, Moscow is only in 13th place among large Russian cities - 45 points. The leaders in this indicator are Omsk and Krasnoyarsk, respectively, with 69 and 68 pharmacies for every 100,000 citizens.
The above statistics do not refer to the volume of drugs sold, however, it is indicative, especially considering the fact that at the beginning of 2015, Moscow was in the top ten in terms of the number of pharmacy outlets.
Sales volume of medicines
When switching to cost indicators, the following situation develops. At the end of 2015, according to the data of the Retail Audit of OTC drugs, the share of Moscow in the total Russian sales amounted to 10.7% (the number of residents of the capital is 8.3% of the population of Russia).
In ruble terms, the capital market of finished medicines grew by 6% over the year, amounting to 85.439 billion rubles. At the same time, in dollar and volume terms, it decreased by 33% and 4%, respectively, stopping at $1.406 billion and 420.7 million packs.
If we consider the Moscow pharmacy market as a whole, the picture is almost similar to the FPP market. The total sales volume in Moscow pharmacies in 2015 amounted to 109.624 billion rubles. (an increase of 8%) or $1.805 billion (a decrease of 32%).
A natural consequence was a decrease in the average cost of an OTC pack purchased by Muscovites from $6.06 in 2014 to $4.29 in 2015. The amount of money spent on average per metropolitan resident per year is $147.96. This is almost three times the national average of $59.94.
Top selling drugs and manufacturers
The position of leaders among drug manufacturers in the Moscow market in last years stable. In 2015, the top five places are occupied by the same companies as in 2014, and in exactly the same order:
- Sanofi-Aventis (share in pharmacy sales volume - 5.6%, in 2014 - 6.1%);
- Bayer Healthcare (respectively, 5.5% and 5.4%);
- Glaxosmithkline (3.5% and 3.9%);
- Servier (3.4% and 3.7%);
- Sandos (3.2% and 3.5%).
The rating of the best-selling finished drugs is also quite stable. In recent years, it has been led by Essentiale N (share in total sales - 0.9% in 2015 and 1.1% in 2014). Next in terms of sales are: Crestor, Detralex, Cialis, Cagozel and Ingavirin. Their share in the total sales volume in Moscow pharmacies is approximately equal and amounts to 0.7% in both 2015 and 2014.
Large drug chains in Moscow
The difficult economic situation, which led, as noted above, to a drop in the capacity of the pharmacy market in physical and dollar terms, did not lead to a decrease in the business activity of the leading players. On the contrary, over the past two years there have been significant changes that have seriously affected the list of the largest Russian and Moscow pharmacy chains.
At the same time, there were significant acquisitions in terms of financial injections (purchase in 2016 of the Capital Apteki chain by Mitten for 5.67 billion rubles), mergers (one of the market leaders of the A.V.E. Group network and another well-known company "36.6 ”), as well as the emergence of new serious players (for example, the Association of Independent Pharmacies - ASNA).
Just the other day, at the end of January 2017, the FAS Department for Moscow announced the discovery of a serious cartel agreement between two participants in the market for the supply of various drugs government agencies– by AMT LLC and BSS LLC. These facts confirm that, despite the fall of the market and the profitability of operations carried out on it, it is still interesting for investors and strategically minded entrepreneurs.
Given the number of pharmacies located in Moscow (at the beginning of 2017 - more than 7.2 thousand points), it is not surprising that among the ten largest pharmacy chains in Russia (as of October 1, 2016, RNC Pharma), five of them have head offices based in the capital . Another one, Neopharm, is in 11th place in terms of the share of the domestic drug market and, accordingly, in 6th place among Moscow chains. The leaders of both lists, that is, the first five metropolitan players are the following pharmacy chains.
Pharmacy chain "ASNA"
The Association of Independent Pharmacies was established in 2005. Being, in fact, an association, in most ratings it still refers to pharmacy chains, since the relationship between ASNA members is much closer than in ordinary associations. The rapid growth of ASNA began in the second half of 2014 and continues to this day. The share of the domestic market occupied by the network increased from 1.3% (mid-2014) to 5.9% (as of October 1, 2016), and the number of outlets increased from 370 to 3509 over the same period of time.
In Moscow, ASNA owns 298 pharmacies, the most famous brands are Pharmstar (11 outlets), Nova Vita (8 pharmacies), IFC Apteki (38 pharmacies), Mizar-N (more than 50 outlets in Moscow and the Moscow region) and many others. The main feature of ASNA is the absence of a stake on one or two leading brands, which allowed the network to achieve a leading position not only in the Russian market as a whole, but also in a much more competitive environment in a particular Moscow segment.
Considering the difficult economic situation, the association is actively promoting the ASNA Savings marketing program, which works in most pharmacies and allows you to save up to 20% of the purchase price when you reach a certain check size.
Pharmacy chain "36.6"
The 36.6 chain for the first time rose to the second place of the largest participants in the Russian pharmacy market in early 2016, when it actually completed the merger with A.V.E. Group. As a result, as of October 1, 2016, the network owns 1,740 retail outlets and the share of total drug sales in Russia is 4.2%. The vast majority of 36.6 pharmacies are located in Moscow and St. Petersburg, so we can say with confidence that, yielding to ASNA in Russia as a whole, the 36.6 chain is confidently leading in the capital.
In addition to the title brand, the network controls the equally well-known Gorzdrav Pharmacies (1246 outlets in total, 699 of them in Moscow), as well as the affiliated A.v.e Luxury and A5. Thanks to this, three price segments have been formed, which 36.6 offers to consumers. Gorzdrav Pharmacies operate as a discounter (the average check in 2016 is 271 rubles), the 36.6 brand belongs to the mass sector (the check is 556 rubles), and the premium segment is represented by the A.v.e Luxury brand (the average check is 3659 rubles in 2016).
The company "36.6" is one of the oldest participants in the modern pharmacy market in Russia, as it was founded in 1991. An indicator of the success of the pharmacy chain is that during 2016 more than 26 billion rubles of debts were paid to suppliers, most of which accounted for the pharmacies of the acquired A.V.E.Group. In addition, at the end of 2015, the company approved a dividend policy for the first time, so after summing up the financial results for 2016, it is possible to pay dividends
Pharmacy chain Rigla
The Rigla chain is an integral part of the largest domestic pharmaceutical holding, Protek, and represents the retail business in it. It led the ranking of pharmacy chains in 2013, but as a result of the sharp growth of the two leaders described above, it moved to third place in 2014-2016.
As of 31.12. In 2016, the network owns 1,768 outlets located in 47 regions of the Russian Federation. 251 pharmacies are located in Moscow, which allows Rigla to take third place not only in the all-Russian market (share of 3.7% as of October 1, 2016), but also in the capital market.
The main brands of the network are the title pharmaceutical markets "Rigla" and operating in the segment of the discounters "Zhivika" and "Be healthy!". One of the main advantages of the company is working with the largest domestic distributor CJSC Protek, which is also part of the holding of the same name.
Pharmacy chain of Erkapharm group of companies
Erkapharm group of companies was established in 1994. Currently, the network includes 324 pharmacies located in 12 regions of Russia. The share of the group as of October 1, 2016 is 2.4% of the all-Russian drug market. This allows the company to take the 5th place among the largest pharmacy chains in the country. The group's share in the capital market is 1.6%.
The chain's main brands are Doctor Stoletov (46 pharmacies in Moscow), Khoroshaya Apteka (16 pharmacies in the capital) and Ozerki, operating mainly in St. Petersburg (6 pharmacies in Moscow and 55 in the northern capital and Leningradskaya areas).
The main feature of the network is the large size of its retail outlets, which allows, with a relatively small number of them, to occupy one of the leading positions in the market. In addition, since 2014, Erkapharm has been a confident leader in terms of revenue from one outlet (5.27 million rubles at the end of 2015)
At the same time, more than half of the group's turnover is achieved through the Ozerki brand, whose pharmacies are located primarily in St. Petersburg and the Leningrad Region, which does not prevent Erkafarm from remaining one of the leaders in the Moscow pharmacy market.
Pharmacy chain "Rainbow-First Aid-Ladushka" (pharmaceutical group "Rosta")
Despite the fact that the head office of the network is located in St. Petersburg, it is one of the leading players not only in Russia, but also in the Moscow pharmacy market. The formation of a large network took place during 2014-2015, when Raduga and First Aid first merged, and then the Ladushka network was acquired. As of October 1, 2016, the share of the United Pharmacy Chain Raduga-First Aid-Ladushka is 2.4% with a total number of outlets of 1155. Of these, 23 First Aid pharmacies and 23 Raduga pharmacies are located in Moscow.
Pharmacy chain "Neopharm"
Neopharm occupies one of the leading positions in the Moscow market, while being 11th among the largest pharmacy chains in Russia. As of October 1, 2016, the company owns 301 retail outlets and the share of the domestic market is 1.4%.
The company is represented by two brands: the titular Neopharma (46 outlets in Moscow) and the Stolichki social pharmacy chain (165 pharmacies in Moscow).
Pharmacy chain "Samson-Pharma"
The network was established in 1993 and is a this moment 66 pharmacies concentrated exclusively in Moscow. This allows Samson-Pharma to control 1% of the Russian market (as of October 1, 2016) and about 10% of the capital market.
The most popular pharmacy chains in Moscow
Research related to the identification of the most popular pharmacy chains in Moscow is ongoing. One of the largest was carried out in the first half of 2015 by the analysts of the Market Leader magazine. The Yandex search engine was chosen as an analysis tool, which evaluates the frequency of mentioning the names of various pharmacy chains on the Internet, while the studies concerned Moscow and the Moscow Region.
By a large margin, the word frequency rating was headed by the Gorzdrav Apteka brand (more than 57,000 queries), which is part of the 36.6 network, followed by Samson-Pharma, Social Pharmacy, and Rigla Apteka. Each of the listed names met more than 10 thousand times a month, the rest of the brands did not reach this indicator.
Conclusion
The pharmacy market of Moscow in 2015-2016 continues to occupy a leading position, both in terms of the volume of drugs sold (10.7% of the country as a whole in 2015) and in terms of the number of operating outlets (7268 pharmacies at the beginning of 2017) . Most of the leading domestic pharmacy chains are represented on the market (with 5 out of the top 10 in Russia). Some of them are beginning active development in other regions, thanks to a relatively stable financial base provided by sales in the capital market.
At the same time, despite the growth in drug sales in ruble terms (by 6% in 2015), in dollar terms and physical terms, the market contracted (by 33% and 4%, respectively, in 2015). Also, the cost of the purchased average package of medicines decreased (from $6.06 in 2014 to $4.29 in 2015). At the same time, Muscovites still spend much more on medicines than the Russian average ($147.96 and $59.94 in 2015, respectively).
Share:
Dmitry Solomnikov
ANALYSIS OF THE RUSSIAN MARKET OF MEDICINES USED FOR TREATMENT OF NEURASTHENIA
Olga Kukhtina
assistant of the department of management and economics of pharmacy Belgorod National Research University;
Russia, Belgorod
Irina Spichak
director for international relations of the institute of medicine, head of the department of management and economics of pharmacy Belgorod National Research University, doctor of pharmaceutical sciences, deputy professor;
Russia, Belgorod
Galina Varenykh
associate professor of department management and economics of pharmacy Belgorod National Research University, candidate of pharmaceutical sciences;
Russia, Belgorod
ANNOTATION
The results of a marketing analysis of the Russian market of drugs used to treat neurasthenia are presented. The structure of drugs by producing countries, origin, composition, forms of release has been studied. The main indicators and trends in the development of the range of medicines have been established.
ABSTRACT
Presents the results of the marketing analysis of the Russian market of medicines used for the treatment of neurasthenia. Studied the structure of medicines on the countries of production, on the origin, on the composition, and on the dosage forms. The basic indicators and trends of development of assortment of medicines.
Keywords : pharmaceutical market, neurasthenia, marketing research, medicines.
keywords: pharmaceutical market, neurasthenia, market research, pharmaceuticals medicines
In modern life, a person is in conditions constant stress. Such a state of emotional instability can cause disturbances in the neuropsychic activity of a person and lead to neurosis. So, one of the most common forms of neurosis is neurasthenia. According to the forecasts of the World Health Organization, by 2020, asthenic disorders and depression will take the 2nd place in terms of frequency of occurrence after cardiovascular diseases.
Neurasthenia is a multifactorial disease (the combined effect of physical and mental factors), so there is a need for complex application various pharmacological groups of drugs (MP) that affect various parts of the pathological process
The problem of people's mental health today is moving from the category of exclusively medical problems, becoming social and urgent for the whole society as a whole. Thus, in connection with high prevalence and the social significance of neurasthenia, it is relevant to study the proposals of the modern drug market, identify the main trends in its formation in order to make decisions on optimizing the assortment.
Purpose of the study– marketing analysis of the Russian market of drugs used to treat neurasthenia
Materials and objects. The objects of the study were official sources of information on registered and approved drugs for medical use in the Russian Federation: State Register Medicines (access mode: http://www.grls.rosminzdrav.ru/), as well as the Register of Medicines of Russia (2016); Vidal Handbook 2016, online resources.
Research methods: content analysis, grouping, ranking, structural, segmentation, comparisons.
Discussion of the research results.
The marketing analysis of the market is based on a methodical approach that includes 5 stages: formation of the LP information array; structural analysis of the range of medicinal products; detailed intragroup analysis of drugs; segmentation analysis by production line and by type of dosage form; formation of an assortment macrocontour of drugs for the treatment of neurasthenia.
Thus, at the first stage of the study, it was established that 275 drugs were registered on the pharmaceutical market of the Russian Federation, taking into account dosages, forms of release and packaging, of which 20 are international non-proprietary names (INN) and 59 trade names (TN).
It was revealed that the assortment structure is formed by 3 classification groups of drugs used for the treatment of neurasthenia, according to the ATC classification. Among them, the leading position is occupied by group N - "Nervous system" - which accounts for 74.6% in terms of the number of trade names and 85.8% in terms of the number of drugs. In second place is group A - "Alimentary tract and metabolism" - 23.7% and 11.3%, respectively. This is followed by group L - "Antineoplastic and immunomodulating agents" (1.7% and 2.9%).
At the third stage, for the purpose of a more detailed study, an intra-group analysis of the assortment of drugs was carried out. So, in particular, in the course of studying the group N - “Nervous system”, it was established that it is formed by 3 subgroups of LP. The leading position is occupied by the group N06B - "Psychostimulants and nootropic drugs", which in terms of the number of trade names is 38.6%, in terms of the number of drugs - 58.9%; the second position is the group N05B - "Anxiolytics", accounting for 36.0% and 54.5%, respectively; the third position belongs to the group N05C - "Homing pills and sedatives" (5.1% and 6.8%).
In the course of the structural analysis of drugs belonging to the subgroup N06B "Psychostimulants and nootropic drugs", it was found that the most widespread (87.0%) falls on INN Piracetam, the second place (8.6%) is occupied by Idebenone, the third place is Pyritinol 2 .2%.
Segmentation analysis on the basis of production revealed the predominance of the share of domestically produced drugs - 79.6%, foreign - 20.4%. Offers of 35 domestic manufacturers of drugs for the treatment of neurasthenia have been registered. Among them, the first place is occupied by Ozon LLC - 22.3%, the second place is taken by Valenta Pharmaceuticals - 12.4%. The third position is occupied by OJSC Sintez and Tatkhimpreparaty with 6.3% respectively. Other manufacturing firms account for 52.7%.
Medicines for the treatment of neurasthenia are available in various dosage forms. As a result of the segmentation of the assortment by dosage forms, it was found that drugs in solid dosage form predominate - 84.4%, in second place are drugs in liquid dosage form - 14.9%, in soft - 0.7%
The largest share in the total range of solid dosage forms is occupied by: tablets - 39.2%; capsules - 21.6; coated tablets - 46 drugs (17.9%); the share of other solid dosage forms is 20.7%.
Further, an analysis of the registration of medicinal products was carried out, which made it possible to establish that in the Russian market for the study period from 2009 to 2014. 168 drugs for the treatment of neurasthenia have been registered. The renewal of the range is 61.1%.
The assortment macrocontour of the market of drugs used to treat neurasthenia has been formed, which is mainly represented by drugs of group N "Nervous system" - 85.8%, the leading place among which is occupied by subgroup N06B "Psychostimulants and nootropic drugs" - 58.9% distribution (87.0%) among the drugs of this group falls on the INN Piracetam. By production, domestic preparations predominate - 79.6%, the manufacturing company is Ozon LLC. The studied assortment in 84.4% of cases is represented by solid dosage forms, mainly in the form of tablets 39.2% The renewal of the range is 61.6% (Fig. 1).
Figure 1. Assortment macrocontour of the Russian pharmaceutical market of drugs used to treat neurasthenia, %
Bibliography:
- Putilina M.V. Features of the treatment of asthenic disorders // Consilium medicum. Neurology. - 2010. - No. 1. - S. 30–35.
- Shavlovskaya O.A. Therapy of asthenic conditions in patients with chronic heart ischemia. - 2014. - No. 9.
The assessment of the capacity of the pharmaceutical market, both as a whole and its individual elements, may vary depending on the source of information. This is because different media outlets may use different ways of grouping pharmaceutical activities into sectors.
2018
Growth in imports of finished drugs to RUB 531 billion (+1.1%). Domestic drugs are coming
The appearance of analogues of foreign drugs on the Russian market led to a reduction in imports in 2018. Thus, the import of finished drugs in the Russian Federation amounted to 531 billion rubles, calculated in RNC Pharma. This is only 1.1% more than a year earlier, when the volume of drugs imported into Russia amounted to 525.5 billion rubles, and in 2017, according to last year's data from RNC Pharma, the positive dynamics of imports of finished drugs reached 8.6%.
In real terms, the volume of deliveries amounted to 1.87 billion packs, which is 7.7% less than in 2017. The volume of imports of bulk drugs (in-bulk) decreased by 5%, which amounted to 4 billion minimum dosage units. In monetary terms, the dynamics of in-bulk imports turned out to be positive: in 2018, products were imported into the country by 10.3% more than a year earlier. But, according to RNC Pharma Development Director Nikolai Bespalov, this is due only to the internal financial processes of companies, and not to changes in pricing policy in Russia.
The maximum import volume, according to RNC Pharma, in 2018 was shown by the Swiss Novartis. The company imported products worth 41.6 billion rubles. (including the cost of customs clearance and VAT). The largest positive dynamics in the volume of medicines supplied to Russia belongs to the French Sanofi, which imported 10% more than in 2017.
As follows from the RNC Pharma report, this was due, among other things, to an increase in the supply of the drug Clexane for the treatment of cardiovascular diseases, as well as drugs for the treatment of patients with mucopolysaccharidosis of the first type Aldurazym. Shipments of these drugs increased by 2.3 and 3.2 times, respectively. At the end of 2018, Aldurasim (laronidase) was included in the Seven High-Cost Nosologies program, one tender for its supply for 625 million rubles. The Ministry of Health has already announced.
Among the companies that, on the contrary, significantly reduced the supply of drugs to Russia, RNC Pharma singled out the Israeli Teva, which reduced the volume of imports in monetary terms by 10%. According to analysts, this was due to a 49% reduction in the supply of Valz, a cardiovascular drug, and a 42% reduction in the antiviral drug, Isoprinosine.
In the segment of bulk drugs, the largest volume of imports in real terms was shown by Sanofi, which imported in-bulk products to Russia for 12 billion rubles. The maximum volume of deliveries of this company fell on a drug for the treatment of diabetes Tujeo-Solostar, as well as the Pentaxim vaccine, which is purchased by the Ministry of Health of the Russian Federation as part of the National Immunization Schedule.
According to Nikolai Bespalov, the main reason for the reduction in drug imports is a decrease in the effective demand of the population - in 2018 real income populations have declined. In addition, a large number of generics appear on the Russian market, which are replacing original drugs, Mr. Bespalov notes. According to him, due to the emergence of analogues, a number of foreign companies refused to localize certain names of their drugs in Russia. Among them, according to him, are Novartis, Johnson & Johnson, Teva and others.
Israeli Teva announced the localization in Russia of the production of Copaxone (glatiramer acetate) for the treatment of multiple sclerosis in 2016 at the facilities of Nanolek. This drug is the most significant in the company's portfolio: in 2017, its sales on the global market amounted to $3.8 billion. In December 2018 Russian company Biocad, which registered an analogue of glatiramer acetate, challenged Teva's prolonged patent for Copaxone at a dosage of 40 mg, gaining the opportunity to sell its generic.
Domestic drugs for the treatment of pulmonary diseases showed a 100% increase over the past three years
During the period from 2015 to 2018, the share of supplies of domestic drugs for the treatment of chronic obstructive pulmonary diseases (COPD) and bronchial asthma (BA) doubled.
More than 70% or 22.1 million packages of drugs used to treat Russian patients in 2017 for such diseases as chronic obstructive pulmonary disease (COPD) and bronchial asthma (BA) were produced by the Russian pharmaceutical company Nativa, the British corporation GlaxoSmithkline, and the German Behringer Ingelheim" and the Anglo-Swedish manufacturer "Astrazeneka".
According to Russian and international clinical standards, combined drugs are used as the basis for the treatment of pulmonary diseases. Over 63% of them are emergency drugs - short-acting beta-agonists (salbutamol, fenoterol, ipratropium bromide + fenoterol). At the same time, the Russian pharmaceutical industry has been producing a new generation of drugs for several years - long-acting bronchodilators and combined drugs (long-acting bronchodilator and inhaled hormone) with the possibility of using them to stop seizures.
Doctors talk about the need to correct the existing bias with the excessive use of short-acting beta-agonists, and replace them with effective modern basic therapy drugs, primarily combination drugs and long-acting bronchodilators.
Combination preparations and long-acting bronchodilators are mostly available in convenient powder form, with no storage temperature restrictions. Outwardly, they look like a portable mini-inhaler, in which a clearly calculated amount of the drug, usually for a 1-2-month course, is extremely easy to use.
Meanwhile, the success of therapy for BA and COPD largely depends on the patient's compliance with the recommendations of the attending physician, whether he takes the recommended drugs in the required dosage and frequency, and also how competently the doctor conducts explanatory work with the patient. Up to 74% of patients take medicines incorrectly due to purely technical errors: it is difficult for them to clearly follow the instructions for using aerosols, where it is necessary to clearly synchronize respiratory efforts with the moment the dosing device is activated, or patients do not take a deep breath before inhaling drugs in the form of a powder, etc. As a result, three out of four patients do not receive an adequate therapeutic effect - at the same time, the use of modern powder inhalers in combination with the correct explanatory work of the doctor solves this problem.
2017
Leading companies in public procurement
The reform of the pharmaceutical industry, initiated by the government in 2008, is actively continuing. The year 2012 was marked by the adoption of a number of important legislative acts, the introduction of amendments and the correction of shortcomings in the current sectoral legislation. At the same time, the government maintains a course towards the development of the domestic pharmaceutical industry and support for the Russian manufacturer.
Received by Ernst&Young
Loading...